TrialThe Lancet. Oncology2018

Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.

Amit M Oza et al.PubMed ↗Publisher ↗

No numbers read from the abstract.